Literature DB >> 8993092

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

S M Essock1, W A Hargreaves, N H Covell, J Goethe.   

Abstract

In our study, we examined the effectiveness of clozapine and compared it to the array of medication alternatives typically used in the public sector. Long-term patients in Connecticut's state hospitals who met Food and Drug Administration criteria for clozapine use were invited to participate in this randomized open-label study. Participants (N = 227) were followed for 2 years. Compared with usual care, clozapine was associated with significantly greater reductions in side effects, disruptiveness, and hospitalization, but was not more effective in reducing symptoms or improving quality of life. The groups did not differ in likelihood of being discharged; however, once discharged, clozapine patients were less likely to be readmitted. The results of our study suggest that, compared with the flexible range of medication alternatives available, clozapine is an effective agent. However, at least with this patient population, clozapine did not produce the dramatic improvements is symptomatology or hospital utilization reported in clinical efficacy trials or suggested by mirror-image studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993092

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  35 in total

Review 1.  Seclusion and restraint for people with serious mental illnesses.

Authors:  E Sailas; M Fenton
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

Authors:  D A Revicki; L Frank
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

4.  Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network.

Authors:  Deborah A Zarin; Julia L Young; Joyce C West
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-01       Impact factor: 4.328

Review 5.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

6.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Authors:  R Rosenheck; J Cramer; W Xu; J Grabowski; R Douyon; J Thomas; W Henderson; D Charney
Journal:  Health Serv Res       Date:  1998-12       Impact factor: 3.402

8.  Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.

Authors:  Shubhra Mace; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

Review 9.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 10.  Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.

Authors:  Sandra L Tunis; Haya Ascher-Svanum; Michael Stensland; Bruce J Kinon
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.